Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1143659 | 0.84 | CSNK1A1 (0.49) | KMT2AKDM4EPTPN11CSNK1A1CLK4 | |
| SCHEMBL10328113 | 0.82 | PIK3CA (0.57) | PIK3CAPIK3CDPIK3CBPIK3R1MTOR | |
| SCHEMBL21121002 | 0.76 | KMT2A (0.58) | PIK3CAPIK3CDPIK3CBKMT2AKDM4E | |
| SCHEMBL245017 | 0.76 | ALDH1A1 (0.63) | PIK3CAPIK3CDPIK3CBKMT2AKDM4E | |
| SCHEMBL26647400 | 0.76 | PIK3CA (0.56) | PIK3CAPIK3CDPIK3CBKMT2AKDM4E | |
| SCHEMBL24196192 | 0.76 | KDM4E (0.69) | PIK3CAPIK3CDPIK3CBKMT2AKDM4E | |
| SCHEMBL25598894 | 0.76 | IKBKB (0.56) | PIK3CAPIK3CDKMT2AKDM4EPIK3R1 | |
| SCHEMBL31254432 | 0.75 | ALDH1A1 (0.66) | KMT2AKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL30656153 | 0.74 | ALDH1A1 (0.58) | KMT2AKDM4EALDH1A1MAPK1HSD17B10 | |
| SCHEMBL22023334 | 0.73 | PIK3CA (0.57) | PIK3CAKDM4EPIK3R1MTORALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-04 | — | — | US | disclosed |
| CN-102639523-A | Substituted (heteroarylmethyl) thiohydantoin useful as anticancer agents | BAYER SCHERING PHARMA AG | 2012-08-15 | — | — | CN | disclosed |
| EP-2475653-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029537-A1 | SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120251551-A1 | Substituted (Heteroarylmethyl)thiohydantoins | TPMT, BPHL, VHL | PIK3CA 4226/4885PIK3CD 4622/4885PIK3CB 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.